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1. Introduction  
Large clinical trials in adult patients at risk for sudden cardiac death (SCD) have proven the 
efficacy of implantable cardioverter defibrillator (ICD) therapy for both secondary and 
primary prevention of SCD (Moss et al., 1996). In 1989, the first use of ICDs in young 
patients was reported (Kral et al., 1989). Since this initial report, ICD therapy has become 
increasingly important as a treatment approach in the pediatric population, despite the lack 
of randomized pediatric ICD studies. Nevertheless, children still present only 1% of all ICD 
recipients. The first large study of  ICD implantations in patients below the age of 20 years 
was reported by Silka et al in 1993 (Silka et al., 1993). Since then many retrospective cohorts 
describing the clinical outcome of pediatric ICD therapy have been published. (Eicken et al., 
2006; Ten Harkel et al., 2005; Heersche et al., 2010). More recently, two large multicenter 
studies evaluating the clinical outcome of ICD therapy in pediatrics and adults with 
congenital heart disease, including more than 200 children were published (Berul et al., 
2008; Von Bergen et al., 2011). These studies have similar results, showing that ICD therapy 
in children appears to be effective, but with a higher rate of inappropriate shock therapy 
and complications as compared with adult series. The growing number of ICD 
implantations in children has now been followed by a decrease in the number of 
complications (Burns et al., 2011). Despite the lack of large randomized trials, efforts have 
been made to develop guidelines for ICD therapy in children. Recommendations for ICD 
therapy in primary and secondary prevention of SCD in adults have been formalized in the 
2006 ACC/AHA guidelines (Zipes et al., 2006). Class I indications in pediatric and 
congenital heart disease (CHD) patients include aborted SCD without reversible cause. 
Sustained ventricular tachycardia (VT) associated with structural heart disease may be an 
ICD indication if not amenable to ablation or surgical resection (Blom 2008; Berul 2009; 
Zipes et al., 2006). In the following we will discuss the role of ICD treatment in children and 
young adults within different disease entities with an increased risk of SCD: 1) primary 
electrical heart disease; 2) cardiomyopathy, either hypertrophic or dilated; 3) operated or 
unoperated congenital heart disease. Finally, we will discuss the effect of ICD therapy on 
the quality of life and the different modalities of programming and implantation. 
2. Primary electrical heart disease 
Among the various disorders, presently known as primary electrical heart disease, the long-
QT syndrome is by far the most prevalent among young patients. The congenital long-QT  
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syndrome (LQTS) is a genetic channelopathy with variable penetrance and characterized by 
prolongation of the QT interval on the electrocardiogram. It is associated with increased 
propensity for polymorphic ventricular tachy-arrhythmias and SCD in young individuals 
with normal cardiac morphology (Goldenberg et al., 2010). To date, more than 500 
mutations have been identified in 12 LQTS genotypes, with the LQTS type 1 (LQT1) and 
LQTS type 2 (LQT2) genotypes accounting for nearly 90% of identified cases. Although 
there is a continuous growth in the number of ICDs used to prevent fatal outcome 
associated with life-threatening arrhythmic episodes in LQTS patients the identification of 
patients that will profit most of ICD implantation remains a challenge. Long QT syndrome 
without symptoms is increasingly recognized as family members are screened. It has, 
however, been studied that the risk of death does not increase by the death of a sibling 
(Kaufman et al., 2008) It is, therefore, important that the decision to implant a defibrillator is 
based on the own risk factors of an LQTS patient (Kaufman et al., 2008). Previous studies of 
highly symptomatic patients were more worrisome. In the era of genetic testing and device 
implantation, overall mortality is low with treatment. Device therapy, although effective, is 
not without complications and should be reserved for high-risk patients (Etheridge et al., 
2007). 
The first-line treatment of patients with LQTS remains the use of beta-blockers. These have 
been shown to be very effective especially in LQT1 and LQT2 patients in the prevention of 
cardiovascular events. However, in large studies a substantial number of LQTS patients 
were not treated by beta-blockers before ICD implantation. (Goldenberg et al., 2010). In 
high-risk patients beta-blockers reduce the risk of adverse events by about 70% (Goldenberg 
et al., 2010). These findings underscore the fact that beta-blocker therapy should be routinely 
administered  in all high risk LQT1 and LQT2 patients without contraindications as a first 
line measure (Goldenberg et al., 2010). Patients with syncope during beta-blocker therapy 
are at high risk of life-threatening events, and ICD therapy should be considered in these 
patients. The risk of beta-blocker failure is highest in young children and in women (Jons et 
al., 2010).  
There is a continuous growth in the number of ICDs in this patient group (Schwartz & 
Crotti 2008). Potentially, life-saving therapies were rendered at a 5% to 6% per year rate 
among those selected for ICD therapy. Similar inappropriate shock frequencies were also 
noted. Secondary prevention, genotype, and QTc predicted those most likely to receive 
appropriate therapy. In a recent study about ICD implantations in LQTS patients 
Schwartz et al showed that especially among the LQT3 subtype many patients were 
asymptomatic before ICD implantation, and probably did not need one (Schwartz et al., 
2010). They showed that some patients in whom an ICD was implanted the supposed high 
risk was questionable. Although the ICD implant frequency is greatest among LQT3 
patients, the greatest save rate has occurred among LQT2 women who were assessed to be 
at high risk (Horner et al., 2010). 
However, when used in a high-risk LQTS population, ICD therapy seems to be a safe option 
(Monnig et al., 2005). Risk factors for appropriate ICD shocks are longer QTc intervals and 
being survivors of a cardiac arrest. However, betablockers should always be added to ICD 
therapy, while some patients might benefit from additional antibradycardia pacing, 
prolonged detection time, and a rate-smoothing algorithm to prevent recurrent episodes 
(Monnig et al., 2005). 
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Fig. 1. Electrocardiogram of a 20-year old woman with the long-QT syndrome. A 
prolongation of the QT-interval of 520 msec is shown (normally less than 440 msec). 
3. Hypertrophic cardiomyopathy 
ICDs have proven effective in preventing SCD in young hypertrophic cardiomyopathy 
(HCM) patients with appropriate intervention rates of 11% for secondary and 4% for 
primary prevention, despite massive left ventricular (LV) hypertrophy, LV outflow 
obstruction, diastolic dysfunction or microvascular ischemia. Targeting candidates for 
prophylactic ICD therapy can be complex, compounded by the unpredictability of the 
arrhythmogenic substrate, the absence of a dominant risk factor, and difficulty in 
assembling randomized trials. However, a single major risk factor is often sufficient to 
justify an ICD, although additional markers and other disease features can resolve 
ambiguous decision-making. Nevertheless, the absence of all risk factors does not convey 
absolute immunity to SCD. However, when presenting with a normal electrocardiogram the 
patients seem at lower risk for cardiac events (McLeod et al., 2009). 
Until now, there is, however, no consensus as to the indication for primary prevention 
with ICD implantation in children (Ostman-Smith 2010). Especially a high rate of 
inappropriate shocks up to 27% and a complication rate up to 17% necessitate careful 
considerations when an ICD implantation is to be planned in the pediatric age group 
(Ostman-Smith 2010). 
The primary prevention risk factors in HCM are 1) family history of HCM related SCDs. 
When a high risk population that received primary prevention with ICD implantation was 
studied the number of appropriate shocks during follow-up did not differ between those 
with a family history of HCM related SCD, whether as an isolated risk factor or combined 
with other risk factors (Bos et al., 2010); 2) episodes of unexplained, recent syncope; 3) 
massive LV hypertrophy >30 mm; 4) nonsustained VT on ambulatory 24-hour Holter ECGs; 
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5) hypotensive or attenuated blood pressure response to exercise (Maron 2010). In addition, 
Gimeno et al recently showed that ventricular arrhythmias during exercise increased the 
risk of SCD as well (Gimeno et al., 2009). However, patients who survive cardiac arrest may 
remain asymptomatic for prolonged periods after the first cardiac event, underscoring the 
unpredictability of the arrhythmogenic substrate in these patients. 
 
 
Fig. 2. Short axis of the left ventricle by echocardiography of a 14-year old boy with 
hypertrophic cardiomyopathy. There is a thickness of 30 mm (normally less than 11 mm). 
In children, the risk of non-sudden cardiac death is as high as sudden cardiac death. 
Extreme left ventricular hypertrophy and a blunted blood pressure response to exercise are 
risk factors (Decker et al., 2009). Risk factors for SCD are extreme left ventricular 
hypertrophy on the electrocardiogram and a septal thickness over 190% of normal, with a 
sensitivity of 91% and a specificity of 78% (Ostman-Smith et al., 2005). Children may be at 
risk for SCD already at young age, and should therefore be screened early in hypertrophic 
cardiomyopathy families  (Ostman-Smith et al., 2008).  
When evaluating HCM patients who underwent ICD placement the number of 
complications is considerable (Lin et al., 2009). In the study of Lin et al 181 patients with a 
mean age of 44 years were investigated. During a follow-up period of 5 years, 65 patients 
(36%) had a total of 88 device related complications including 42 (23%) patients with 
inappropriate shocks. Younger age and atrial fibrillation were associated with an increased 
risk of inappropriate ICD discharges. It is concluded that the high incidence of 
complications should be taken into account when considering ICD implantation in a high-
risk HCM patient (Lin et al., 2009). 
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4. Congenital heart disease 
Although most patients who are being operated for their congenital heart disease presently 
survive their surgery and lead a relatively normal life, a substantial portion of patients 
develop symptoms of heart failure or rhythm abnormalities in due time.  In adult patients 
with ischemic or non-ischemic cardiomyopathy an LV ejection fraction below 30% is 
considered a clear indication for primary prevention with ICD implantation (Moss et al., 
2002; Bardy et al., 2005). Risk stratification for primary prevention remains highly complex 
and is usually individualized, based on a variety of surgical, hemodynamic, 
electrocardiographic, and electrophysiologic factors (McLeod et al., 2010). However, some 
authors advocate that also for patients with congenital heart disease an LV ejection fraction 
below 30% as single risk factor is sufficient reason to implant an ICD (Silka & Bar-Cohen 
2008), which is argued by others (Triedman 2008). Since the overall rate of SCD is 5 to 10 
times lower than that observed in high-risk cardiomyopathy patients, the life expectancy in 
CHD patients is much larger. Furthermore, in CHD patients vascular access is often 
difficult, and the rate of device associated cardiac events and lead-failure is much higher, 
and they have variable cardiac anatomy. Therefore, the results of the large ICD trials cannot 
simply be extrapolated to the population of CHD patients. Other risk factors have to be 
taken into account before deciding to implant an ICD (Triedman 2008).  With the increasing 
knowledge of rhythm abnormalities in congenital heart disease and the emergence of 
interventional electrophysiologic techniques some ventricular arrhythmias can be treated by 
catheter ablation (Walsh 2007). ICD implantation remains to be limited to otherwise 
untreatable rhythm abnormalities. 
In a study of Yap et al more than 60% of the patients with an ICD and a congenital heart 
disease had a tetralogy of Fallot (Yap et al.,. 2007). However, the overall complication rate 
in the Fallot patients was higher as compared to other congenital heart defects, the 
number of inappropriate shocks was high (40%), while the number of appropriate shocks 
was low as compared to other patients (18% versus 33%). When compared with an older 
ICD population with dilated cardiomyopathy (DCM), the Tetralogy of Fallot patients 
were more likely to have experienced oversensing (45 vs. 13%; P < 0.02), inappropriate 
anti-tachycardia pacing delivery (20 vs. 2%; P < 0.05), and inappropriate cardioversion (25 
vs. 4%; P = 0.06) and less likely to receive appropriate therapies (Witte et al., 2008). On the 
other hand, Khairy et al studied 121 Fallot patients who received an ICD for primary 
(N=68) or secondary (N=53) prevention. During follow-up the number of appropriate 
shocks was considerable (30% of patients). This was, however, at the cost of a 5.8% yearly 
incidence of inappropriate shocks, and the occurrence of complications in 36 patients, 
mostly (70%) lead-related (Khairy et al., 2008). In Fallot patients with unstable ventricular 
tachycardia, their rhythm abnormalities may in some patients be treated by catheter 
ablation (Kriebel et al., 2007). 
5. ICD programming 
In children with ICDs, the risk of inappropriate shock therapy is significantly higher as 
compared to adult studies. Pediatric ICD series with mean intervals of follow-up between 29 
and 51 months have reported 20% to 50% inappropriate shock therapy. These shocks may 
have a negative impact on the quality of life, and can induce secondary arrhythmias.  
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Tomaske 
2008 
Stephenson 
2006 
Kriebel 
2006 
Cannon 
2006 
Number 15 22 8 8 
Age (yr) 12.5 8.9 0.3-8 1-29 
Weight (kg) 36.5 25.5 4-29  
Follow-up (mo) 22 29 14.5 22 
Appr Shocks 4 7 2 2 
Inappr Shocks 3 4 0 3 
Revision 4 7 2 3 
Table 1. Outcomes of extracardiac ICD implantations in young patients and patients with 
congenital heart disease. Results are comparable to transvenous approaches. 
Inappropriate shocks in children are mostly caused by sinus tachycardia or supraventricular 
tachycardia. High sinus rates up to 200 per minute are not uncommon in children and 
patients with congenital heart disease have a high incidence of atrial arrhythmias, mostly 
intraatrial reentrant tachycardia. Implantation of a dual chamber ICD system can potentially 
reduce the incidence of inappropriate discharges attributable to the misclassification of sinus 
tachycardia or supraventricular tachycardia as a ventricular event. In a recent multicenter 
study the difference of appropriate and inappropriate shocks in a single chamber or dual 
chamber device in patients <30 years old was investigated (Lawrence et al., 2009). The 
authors found no differences between single chamber or dual chamber systems regarding 
the occurrence of appropriate or inappropriate shocks, irrespective of underlying 
cardiovascular disorder or type of ICD system. (Lawrence et al., 2009). T-wave sensing is 
another important cause of inappropriate shock therapy especially in the group of patients 
with long QT syndrome. Exercise tests are required to obtain maximal heart rate and to 
evaluate T wave sensing during high heart rates. QRS discrimination or atrial discrimination 
algorithms can be helpful tools to prevent some of these problems. β-blockade can also be a 
practical therapy to avoid inappropriate ICD shock for supraventricular tachycardias or 
sinus tachycardia. However, the most important measure to reduce inappropriate shocks is 
careful ICD programming of the individual child with regard to detection rate and time 
immediately after ICD implantation. In a recent article several programming tips have been 
given (Khairy & Mansour 2011). Since sinus tachycardia and supraventricular tachycardia 
may have frequencies as high as 200 bpm, most young patients have a ventricular 
fibrillation zone programmed up to 220 bpm. Concerning detection times there is a 
compromise between overtreating otherwise self-terminating events and delaying therapy 
for potentially unstable arrhythmias. Detection times as long as 18 of 24 intervals or even 30 
of 40 intervals have been advocated with no increase in adverse events. Antitachycardia 
pacing (ATP) has been shown to be effective in the majority of congenital heart disease 
patients, thereby lowering the number of shocks. 
Although routine testing of the defibrillation threshold (DFT) is not necessary during 
follow-up of pediatric ICD patients, any clinical change or problem should be evaluated 
immediately and DFT testing should also be considered in this situation. (Theuns & Gold, 
2010). In young children with subcutaneous ICD systems regular DFT testing should be 
considered during growth. 
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6. Complications 
There seem to be differences in the frequency of ICD-related complications between children 
and adults. However, due to the small number of patients in pediatric series it is difficult to 
estimate the true incidence of ICD related complications in children. (Shah et al., 2009). 
Implantation procedure-related complications include pocket infection, pocket hematoma, 
microdislodgement requiring lead manipulation , hemothorax, superior vena cava 
syndrome, pneumonia, electromechanical dissociation requiring cardiopulmonary 
resuscitation and second degree burns from repeated external rescue shocks (Shah et al., 
2009). Especially the number of infections seem to be higher in children as compared to 
adults (Link et al., 1999). The most common ICD system related adverse effect is the high 
incidence of inappropriate shocks and a high incidence of lead failures in children. 
Inappropriate shocks are usually related to the occurrence of sinus tachycardia, 
supraventricular tachycardia, T wave oversensing or QRS complex double sensing. Lead 
failures are strongly related to the size of the patient. The youngest and smallest patients 
have the highest risk of lead complications. Furthermore, higher levels of exercise and 
activity in the pediatric population may increase the amount of lead problems.  
7. Mode of ICD implantation 
In children or young patients with congenital heart defects it is often not possible to make 
use of routine transvenous ICD systems. Underlying causes are the size of the patient or 
structural heart diseases with residual intracardiac shunts and abnormal systemic venous 
pathways. Various modifications have been used to implant ICDs in patients with limited 
venous access (Cannon et al., 2006; Bove et al., 2010; Greene et al., 2004; Kriebel et al., 
2006; Stephenson et al., 2006; Tomaske et al., 2008). These include subcutaneous patches, 
epicardial and pleural lead positioning, use of the subxiphoid incision, or direct 
transatrial approach. It is important that the technique used is individualized in the 
diverse population of children and young patients with congenital heart disease in need 
for ICD placement (Stephenson et al., 2006). Recently,  Radbill et al compared the use of 
transvenous ICDs with nontransvenous systems in a group of pediatric and congenital 
heart disease patients  (Radbill et al., 2010). Although no differences were reported 
considering appropriate or inappropriate shocks there was a significantly higher amount 
of ICD system failure in the nontransvenous group. System survival at 12, 24, and 36 
months was 73%, 55% and 49% in the nontransvenous group compared to 91%, 83% and 
76% in the transvenous group. Causes of system failure in the nontransvenous group 
included pace-sense lead failure, shock coil failure, generator migration, and loosened set-
screw connection. 
Recently, the search for avoidance of transvenous lead placement has resulted in the 
development of an entirely subcutaneous ICD system (Bardy et al., 2010). The system 
consists of a parasternal electrode and a left lateral thoracic pulse generator. In a trial of 55 
adult patients it was shown as effective in terminating ventricular tachyarrhythmias with 
little complications  during a 10-month follow-up period. This subcutaneous ICD system can 
also be used in older children and has been reported in two children of 10 and 12 years old 
(34 and 35 kg body weight) (McLeod and McLean 2010). In both children this device was 
implanted without complications, and no adverse events occurred during an 8- and 5-month 
follow-up period (McLeod & McLean 2010).  
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Fig. 3. Chest X-ray of a 6-month old child with an ICD. The active can is placed abdominally, 
and the pacing wires are placed epicardially. A subcutaneous patch is in use for eventual 
shocks. 
Another approach is the placement of the ICD in the axilla. The usual infraclavicular 
placement of a transvenous ICD can cause a quite visible scar with a suboptimal cosmetic 
result. Furthermore, straps can rub and cause irritation at this site (Collins et al., 2009; 
Rausch et al., 2010). In a large retrospective review it was shown that there were no 
differences between the axillary and infraclavicular technique in implant characteristics, 
lead longevity, implant complications, lead fractures or dislodgements, inappropriate ICD 
discharges, or device infections (Rausch et al., 2010). 
8. Home monitoring 
Since 2000 a remote control system was introduced for the follow-up of ICD patients. 
Through this system data from the implanted device are transmitted  to a website once a 
day as well as immediately following an arrhythmia. By this method changes in ICD 
function, lead problems, and asymptomatic arrhythmias can be detected earlier without the 
patient actually visiting the hospital. It has been shown that the events as send by the home 
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monitoring system show excellent comparability to the data as obtained by standard clinical 
evaluation (Perings et al., 2011). The home monitoring system can detect several, otherwise 
asymptomatic episodes enhancing prompt detection of for instance lead problems and 
facilitates management decisions (Varma et al., 2010). Most patients show a high level of 
acceptance and satisfaction of this new system after a mean follow-up period of 1 year, with 
only some refusing the home monitoring (Ricci et al., 2010). Until now, however, this system 
has mostly been used in the adult population, and data about the appropriateness in 
pediatrics are as yet lacking.  
9. Quality of life 
With the increasing number of ICDs in young patients the psychological effects has been 
studied as early as 1996 (Dubin et al., 1996). Nearly 75% of the patients felt their health was 
good to excellent with 40% reporting improvement since ICD implantation. All felt capable 
of performing daily activities (Dubin et al., 1996).  
The implantation of an ICD has a great impact on the quality of life of these patients. These 
psychological effects have sofar been investigated by many authors (Herrmann et al., 1997). 
The poor psychosocial outcome in these patients may be related to the underlying 
cardiovascular condition (Burke et al., 2003), or it may be the effect of surviving an out of 
hospital cardiac arrest, not related to the treatment received (Kamphuis et al., 2002). It has 
been found that the lasting psychological distress will not dissipate spontaneously or 
naturally and that psychosocial intervention may be warranted (Kamphuis et al., 2003). The 
most common psychological problems are depression and anxiety. Depressive symptoms 
persist over time, and are associated with a higher incidence of shock therapy (Suzuki et al., 
2010). However, concerns about the ICD has been found a predictor of psychological 
morbidity independently of the number of shocks (Pedersen et al., 2005). On the other hand, 
Luyster et al found no relation between number of shocks and anxiety (Luyster et al., 2006). 
They found especially a higher level of perceived resource loss to be associated with higher 
levels of both anxiety and depression (Luyster et al., 2006). 
The growing pediatric ICD population stresses the need to evaluate the quality of life in 
this group of ICD recipients. Adult patients with ICDs show significantly worse 
psychological and physical functioning. Behavioral changes have been reported such as 
reduced activity, avoidance, depression, and anxiety, especially in those who had received 
ICD shocks. These finding in adults could not be confirmed in a recent study in a group of 
pediatric ICD recipients. In this study, cardiac illness severity and ICD shock therapy 
were not significantly associated with anxiety, depression, quality of life, or family 
functioning. 
Recently, we have also evaluated health-related quality of life study in 30 Dutch pediatric 
ICD recipients using different quality of life questionnaires. This study showed that 
pediatric ICD recipients showed more problems in the domains of motor functioning, sleep, 
work/school, negative emotions, and anxiety. Furthermore, worry and anxiety were 
significantly associated with the number of ICD shocks (unpublished data). These findings 
indicate that avoidance or reduction of inappropriate shocks is one of the most important 
steps to improve quality of life. Furthermore, it emphasizes the need of proper guidance 
and, if necessary, implementation of psychological interventions. Screening for 
cardiovascular diseases may have its own impact, Children who were genetically tested 
carriers showed to have a reduced psychological well-being (Smets et al., 2008). 
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Fig. 4. An ICD strip of an appropriate shock is shown. Fast ventricular tachycardia is 
followed by a 21-J shock which terminated the tachycardia. This is followed by an escape 
rhythm with broad QRS complexes. 
10. Conclusions 
ICD implantations are increasingly performed in children and young adults with a variety 
of underlying cardiac disorders. Although the effectiveness of ICD therapy in this specific 
population is good, there are concerns about the high number of inappropriate shocks and 
lead problems. New developments include the complete subcutaneous device and home 
monitoring systems. Although the overall quality of life usually is good, several patients 
need psychological support, and this support has to be included in regular follow-up 
programs. 
11. References 
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, 
Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo 
ES, Fishbein DP, Luceri RM, Ip JH. (2005) Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-
defibrillator for congestive heart failure. N Engl J Med 352: 225–237. 
www.intechopen.com
 ICD Implantations in the Pediatric and Young Adult Population 
 
177 
Bardy GH, Smith WM, Hood MA, Grozier IG, Melton IC, Jordaens L, Theuns D, Park RE, 
Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer 
SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder IC, Wilde AA, Van 
Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. (2010) An entirely 
subcutaneous implantable cardioverter-defibrillator New Engl J Med 363:36-44. 
Berul CL. (2009) Implantable cardioverter defibrillator criteria for primary and secondary 
prevention of pediatric sudden cardiac death. PACE 32:S67-S70. 
Berul CL, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, Cannon BC, 
Alexander ME, Triedman JK, Walsh EP, Friedman RA. (2008) Results of a 
multicenter retrospective implantable cardioverter-defibrillator registry of pediatric 
and congenital heart disease patients. J Am Coll Cardiol 51:1685-1691. 
Blom NA. (2008) Implantable cardioverter-defibrillators in children. PACE 31:S32-S34. 
Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajji P, Nishimura RA, Gersh BJ, Ommen SR. 
(2010) Role of family history of sudden death in risk stratification and prevention of 
sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am 
J Cardiol 106:1481-1486. 
Botsch MP, Franzbach B, Opgen-Rhein B, Berger F, Will JC. (2010) ICD therapy in children 
and young adults: low incidence of inappropriate shick delivery. PACE 33:734-741. 
Bove T, Francois K, De Caluwe W, Suys B, De Wolf D. (2010) Effective cardioverter 
defibrillator implantation in children without thoracotomy: a valid alternative. Ann 
Thorac Surg 89:1307-1309. 
Burke JL, Hallas CN, Clark-Carter D, White D, Connelly D. (2003) The psychosocial impact 
of the implantable cardioverter defibrillator: A meta-analytic review. British Journal 
of Health Psychology 8:165-178. 
Burns KM, Evans F, Kaltman JR. (2011) Pediatric ICD utilization in the United States from 
1997 to 2006. Heart Rhythm 8:23-28. 
Cannon BC, Friedman RA, Fenrich AL, Fraser CD, McKenzie ED, Kertesz NJ. (2006) 
Innovative techniques for placement of implantable cardioverter defibrillator leads 
in patients with limited venous access to the heart. PACE 29:181-187. 
Collins KK, Runciman M, Rausch CM, Schaffer MS. (2009) Toward improved cosmetic 
results: a novel technique for the placement of a pacemaker or internal 
cardioverter/ defibrillator generators in the axilla of young patients. Pediatr Cardiol 
30:1157-1160. 
Daubert JP, Zareba W, Rosero SZ, Budzikowski A, Robinson JL, Moss AJ. (2007) Role of 
implantable cardioverter defibrillator therapy in patients with long QT syndrome. 
Am Heart J 153:553-558. 
Decker JA, Rossano JW, Smith O, Cannon B, Clunie SK, Gates C, Jefferies JL, Kim JJ, Price JF, 
Dreyer WJ, Towbin JA, Denfield SW. (2009) Risk factors and mode of death in 
isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 54:250-254. 
DeMaso DR, Lauretti A, Spieth L, Van Der Feen JR, Jay KS, Gauvreau K, Walsh EP, Berul CI. 
(2004) Psychosocial factors and quality of life in children and adolescents with 
implantable cardioverter-defibrillators. Am J Cardiol 93:582-587. 
Dubin AM, Batsford WP, Lewis RJ, Rosenfeld LE. (1996) Quality-of-life in patients receiving 
implantable cardioverter defibrillators at or before age 40. PACE 19:1555-1559. 
Eicken A, Kolb C, Lange S, Brodherr-Heberlein S, Zrenner B, Schreiber C, Hess J. (2006) 
Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol 107:30-35. 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
178 
Etheridge SP, Sanatani S, Cohen MI, Albaro CA, Saarel EV, Bradley DJ. (2007) Long QT 
syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 
50:1335-1340. 
Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, Lamblase P, 
McKenna WJ, Elliott PM. (2009) Exercise-induced ventricular arrhythmias and risk 
of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 
30:2599-2605. 
Goldenberg I, Bradley J, Moss A, McNitt S, Polonsky S, Robinson JL, Andrews M, Zareba W. 
(2010) Beta-blocker efficacy in high-risk patients with the congenital long-QT 
syndrome types 1 and 2: implications for patient management. J Cardiovasc 
Electrophysiol 21:893-901. 
Greene AE, Moak JP, Di Russo G, Berger JT, Heshmat Y, Kuehl KS. (2004) Transcutaneous 
implantation of an internal cardioverter defibrillator in a small infant with 
recurrent myocardial ischemia and cardiac arrest simulating sudden infant death 
syndrome. PACE 27:112-116. 
Heersche JHM, Blom NA, Van de Heuvel F, Blank C, Reimer AG, Clur SA, Witsenburg M, 
Ten Harkel ADJ. (2010) Implantable cardioverter defibrillator therapy for 
prevention of sudden cardiac death in children in The Netherlands. PACE 33:179-
185. 
Herrmann C, von zur Mühen F, Buss U, Kemper S, Wantzen C, Gonska BD. (1997) 
Standardized assessment of psychological well-being and quality-of-life in patients 
with implanted defibrillators. PACE 20:95-103. 
Horner JM, Kinoshita M, Webster TL, Haglund CM, Friedman PA, Ackerman MJ. (2010) 
Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a 
single-center experience. Heart Rhythm 7:1616-1622. 
Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, Qi M, Robinson JL. (2010) Risk of 
fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll 
Cardiol 55:783-788. 
Kamphuis HCM, de Leeuw JRJ, Derksen R, Hauer R, Winnubst JAM. (2002) A 12-month 
quality of life assessment of cardiac arrest survivors treated with or without an 
implantable cardioverter defibrillator. Europace 4:417-425. 
Kamphuis HCM, de Leeuw JRJ, Derksen R, Hauer RNW, Winnubst JAM. (2003) Implantable 
cardioverter defibrillator recipients: quality of life in recipients with and without 
ICD shock delivery: A prospective study. Europace 5:381-389. 
Kaufman ES, McNitt S, Moss AJ, Zareba W, Robinson JL, Hall WJ, Ackerman MJ, Benhorin J, 
Locati ET, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. 
(2008) Risk of death in the long QT syndrome when a sibling has died. Heart 
Rhythm 5:831-836. 
Khairy P & Mansour F. (2011) Implantable cardioverter-defibrillators in congenital heart 
disease: 10 programming tips. Heart Rhythm. 
Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, Fernandes SM, 
Beauchesne L, Therrien J, Chetaille P, Gordon E, Muhll IV, Cecchin F. (2008) 
Implantable cardioverter-defibrillatos in tetralogy of Fallot. Circulation 117:363-370. 
Kral MA, Spotnitz HM, Hordof A, Bigger JT Jr, Steinberg JS, Livelli FD Jr. (1989) Automatic 
implantable cardioverter defibrillator implantation for malignant ventricular 
arrhythmias associated with congenital heart disease. Am J Cardiol. 63:118-9. 
www.intechopen.com
 ICD Implantations in the Pediatric and Young Adult Population 
 
179 
Kriebel T, Ruschewski W, Gonzalez M, Walter K, Kroll J, Kampmann C, Heinemann M, 
Schneider H, Paul T. (2006) ICD implantation in infants and small children. The 
extracardiac technique. PACE 29:1319-1325. 
Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. (2007) Radiocontact mapping and 
radiofrequency catheter ablation of fast and hemodynamically unstable ventricular 
tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 50:2162-
2168. 
Lawrence D, Von Bergen N,  Law IH, Bradley DJ, Dick II M, Frias PA, Streiper MJ, Fischbach 
PS. (2009) Inappropriate ICD discharges in single-chamber versus dual-chamber 
devices in the pediatric and young adult population. J Cardiovasc Electrophysiol 
20:287-290. 
Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. (2009) Device 
complications and inappropriate implantable cardioverter defibrillator shocks in 
patients with hypertrophic cardiomyopathy. Heart 95:709-714. 
Link MS, Hill SL, Cliff DL, Swygman CA, Foote CB, Homoud MK, Wang PJ, Estelli M, Berul 
CI. (1999) Comparison of frequency of complications of implantable cardioverter-
defibrillators in children versus adults. Am J Cardiol 83:263-266. 
Luyster FS, Hughes JW, Waechter D, Josephson R. (2006) Resource Loss Predicts Depression 
and Anxiety Among Patients Treated With an Implantable Cardioverter 
Defibrillator. Psychosom Med 68:794-800. 
Maron BJ. (2010) Risk stratification and role of implantable defibrillators for prevention of 
sudden death in patients with hypertrophic cardiomyopathy. Circ J 74:2271-2282. 
Maron BJ, Haas TS, Shannon KM, Almquist AK, Hodges JS. (2009) Long-term survival after 
cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 6:993-997. 
McLeod KA & McLean A. (2010) Implantation of a fully subcutaneous ICD in children. 
PACE 1-4. 
McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR. (2009) Outcome 
of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J 
Am Coll Cardiol 54:229-233. 
McLeod CJ, Kapa S, Asirvatham SJ. (2010) Implantable cardioverter-defibrillator therapy in 
congenital heart disease. Expert Rev Med Devices 7:1-3. 
Monnig G, Kobe J, Loher A, Eckardt L, Wedekind H, Scheld HH, Haverkamp W, Milberg P. 
Breithardt G, Schulze-Bahr E, Bocker D. (2005) Implantable cardioverter-
defibrillator therapy in patients with congenital long-QT syndrome: a long-term 
follow-up. Heart Rhythm 2:497-504. 
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannon DS, Daubert JP, Higgins SL, 
Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial 
II Investigators. (2002) Prophylactic implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection fraction. N Engl J Med. 346: 877–883. 
Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, 
Waldo AL, Wilber D, Brown MW, Heo M. (1996) Improved survival with an 
implanted defibrillator in patients with coronary disease at high risk for ventricular 
arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N 
Engl J Med. 335:1933-40.  
Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. (2005) 
Echocardiographic and electrocardiographic identification of those children with 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
180 
hypertrophic cardiomyopathy who should be considered at high-risk of dying 
suddenly. Cardiol Young 15:632-642. 
Ostman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, Bowker C, 
Verdicchio M. (2008) Age- and gender-specific mortality rates in childhood 
hypertrophic cardiomyopathy. Eur Heart J 29:1160-1167. 
Ostman-Smith I. (2010) Hypertrophic cardiomyopathy in childhood and adolescence – 
strategies to prevent sudden death. Fundam Clin Pharmacol 24:637-652. 
Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. (2005) Concerns 
about the implantable cardioverter defibrillator: A determinant of anxiety and 
depressive symptoms independent of experienced shocks. Am Heart J 149:664-669. 
Perings C, Bauer WR, Bondke HJ, Mewis C, James M, Bocker D, Broadhurst P, Korte T, Toft 
E, Hintringer F, Clementy J, Schwab JO. (2011) Remote monitoring of implantable-
cardioverter defibrillator: results from the reliability of IEGM online interpretation 
(RIONI) study. Europace 13:221-229. 
Radbill AE, Triedman JK, Berul CI, Fynn-Thompson F, Atallah J, Alexander ME, Walsh EP, 
Cecchin F. (2010) System survival of nontransvenous implantable cardioverter-
defibrillators compared to transvenous implantable cardioverter-defibrillators in 
pediatric and congenital heart disease patients. Heart Rhythm 7:193-198. 
Rausch CM, Hughes BH, Runciman M, Law IH, Bradley DJ, Sujeev M, Duke A, Schaffer M, 
Collins KK. (2010) Axillary versus infraclavicular placement for endocardial heart 
rhythm devices in patients with pediatric and congenital heart disease. Am J Cardiol 
106:1646-1651. 
Ricci RP, Morichelli L, Quarta L, Sassi A, Porfill A, Laudadio MT, Gargaro A, Santini M. 
(2010) Long-term patient acceptance of and satisfaction with implanted device 
remote monitoring. Europace 12:674-679. 
Schwartz PJ & Crotti L. (2008) Ion channel diseases in children: manifestations and 
management. Curr Opin Cardiol 23:184-191. 
Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, Gasparini M, Wilde 
AAM, Knops RE, Denjoy I, Toivonen L, Monnig G, Al-Fayyadh M, Jordaens L, 
Borggrefe M, Holmgren C, Brugada P, De Roy L, Hohnloser SH, Brink PA. (2010) 
Who are the Long-QT syndrome patients who receive an implantable cardioverter-
defibrillator and what happens to them? Data from the European Long-QT 
syndrome implantable cardioverter-defibrillator (LQTS ICD) registry. Circulation 
122:1272-1282. 
Sears SF, Burns JL, Handberg E, Sotile WM, Conti JB. (2001) Young at heart: understanding 
the unique psychosocial adjustment of young implantable cardioverter defibrillator 
recipients. PACE 24:1113-1117. 
Sears SF, St.Amant JB, Zeigler V. (2009) Psychosocial considerations for children and young 
adolescents with implantable cardioverter defibrillators: an update. PACE 32:S80-
82. 
Shah MJ. (2009) Implantable cardioverter defibrillator-related complications in the pediatric 
population. PACE 32:S71-S74. 
Silka MJ, Kron J, Dunnigan A, Dick M 2nd. (1993) Sudden cardiac death and the use of 
implantable cardioverter-defibrillators in pediatric patients. The Pediatric 
Electrophysiology Society. Circulation. 87:800-7. 
www.intechopen.com
 ICD Implantations in the Pediatric and Young Adult Population 
 
181 
Silka MJ & Bar-Cohen Y. (2008) Should patients with congenital heart disease and a systemic 
ventricular ejection fraction less than 30% undergo prophylactic implantation of an 
ICD? Patients with congenital heart disease and a systemic ventricular ejection 
fraction less than 30% should undergo prophylactic implantation of an implantable 
cardioverter defibrillator. Circ Arrhythmia Electrophysiol 298-306. 
Smets EMA, Stam MMH, Meulenkamp TM, Van Langen IM, Wilde AAM, Wiegman A, De 
Wert GM, Tibben A. (2008) Health-related quality of life of children with a positive 
carrier status for inherited cardiovascular diseases. Am J Med Genet Part A 
146A:700-707. 
Stephenson EA, Batra AS, Knilans TK, Gow RM, Gradaus R, Balaji S. (2006) A multicenter 
experience with novel implantable cardioverter defibrillator configuration in the 
pediatric and congenital heart disease population. J Cardiovasc Electrophysiol 17:41-
46. 
Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K, Suzuki A, Ejima K, 
Manaka T, Shoda M, Ishigooka J, Kasanuki H, Hagiwara N. (2010) Prevalence and 
persistence of depression in patients with implantable cardioverter defibrillators: a 
2-year longitudinal study. PACE 33:1455-1461. 
Ten Harkel ADJ, Blom NA, Reimer AG, Tukkie R, Sreeram N, Bink-Boelkens MTE. (2005) 
Implantable cardioverter defibrillator implantation in children in The Netherlands. 
Eur J Pediatr 164:436-441. 
Theuns DAMJ  & Gold MR. (2010) Defibrillator threshold testing at implantation: can we 
predict the patient with a high defibrillation threshold? Europace 12:309-310. 
Tomaske M, Pretre R, Rahn M, Bauersfeld U. (2008) Epicardial and pleural lead ICD systems 
in children and adolescents maintain functionally over 5 years. Europace 10:1152-
1156. 
Triedman JK. (2008) Should patients with congenital heart disease and a systemic 
ventricular ejection fraction less than 30% undergo prophylactic implantation of an 
ICD? Implantable cardioverter defibrillator implantation guidelines based solely on 
left ventricular ejection fraction do not apply to adults with congenital heart 
disease. Circ Arrhythmia Electrophysiol 1:307-316. 
Varma N, Michalski J, Epstein AE, Schweikert R. (2010) Automatic remote monitoring of 
implantable cardioverter-defibrillator lead and generator performance . The lumos-
T safely reduces routine office device follow-up (TRUST) trial. Circ Arrhythm 
Electrophysiol 3:428-436. 
Von Bergen NH, Atkins DL, Dick II M, Bradley DJ, Etheridge SP, Saarel EV, Fischbach PS, 
Balaji S, Sreeram N, Evans WN, Law IH. (2011) Multicenter study of the 
effectiveness of implantable cardioverter defibrillators in children and young 
adults with heart disease. Pediatr Cardiol 32:399-405. 
Walsh EP. (2007) Interventional electrophysiology in patients with congenital heart disease. 
Circulation 115:3224-3234. 
Witte KK, Pepper CB, Cowan JC, Thomson JD, English KM, Blackburn ME. (2008) 
Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of 
Fallot. Europace 10:926-930. 
Yap SC, Roos-Hesselink JW, Hoendermis ES, Budts W, Vliegen HW, Mulder BJM, Van Dijk 
APJ, Schalij MJ, Drenthen W. (2007) Outcome of implantable cardioverter 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
182 
defibrillators in adults with congenital heart disease: a multicenter study. Eur Heart 
J 28:1854-1861. 
Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein 
G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, 
Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin 
JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers 
JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey 
A, Tamargo JL, Zamorano JL (2006). American College of Cardiology/American 
Heart Association Task Force; European Society of Cardiology Committee for 
Practice Guidelines; European Heart Rhythm Association; Heart Rhythm 
Society.ACC/AHA/ESC 2006 Guidelines for Management of Patients With 
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of 
the American College of Cardiology/American Heart Association Task Force and 
the European Society of Cardiology Committee for Practice Guidelines (writing 
committee to develop Guidelines for Management of Patients With Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death): developed in 
collaboration with the European Heart Rhythm Association and the Heart Rhythm 
Society. Circulation 114:e385-484. 
www.intechopen.com
Cardiac Defibrillation - Mechanisms, Challenges and Implications
Edited by Prof. Natalia Trayanova
ISBN 978-953-307-666-9
Hard cover, 248 pages
Publisher InTech
Published online 26, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The only known effective therapy for lethal disturbances in cardiac rhythm is deï¬​brillation, the delivery of a
strong electric shock to the heart. This technique constitutes the most important means for prevention of
sudden cardiac death. The efficacy of defibrillation has led to an exponential growth in the number of patients
receiving implantable devices. The objective of this book is to present contemporary views on the basic
mechanisms by which the heart responds to an electric shock, as well as on the challenges and implications of
clinical defibrillation. Basic science chapters elucidate questions such as lead configurations and the reasons
by which a defibrillation shock fails. Chapters devoted to the challenges in the clinical procedure of defibrillation
address issues related to inappropriate and unnecessary shocks, complications associated with the
implantation of cardioverter/defibrillator devices, and the application of the therapy in pediatric patients and
young adults. The book also examines the implications of defibrillation therapy, such as patient risk
stratification, cardiac rehabilitation, and remote monitoring of patient with implantable devices.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ten Harkel Arend DJ and Blom Nico A (2011). ICD Implantations in the Pediatric and Young Adult Population,
Cardiac Defibrillation - Mechanisms, Challenges and Implications, Prof. Natalia Trayanova (Ed.), ISBN: 978-
953-307-666-9, InTech, Available from: http://www.intechopen.com/books/cardiac-defibrillation-mechanisms-
challenges-and-implications/icd-implantations-in-the-pediatric-and-young-adult-population
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
